Want to see JP:4880 full AI Analyst Report?
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥294.00 - ¥723.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥6.79B
Enterprise Value¥1.41B
Total Cash (Recent Filing)¥4.79B
Total Debt (Recent Filing)¥25.26M
Price to Earnings (P/E)95.2
Beta0.85
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.5%
Share Statistics
EPS (TTM)3.56
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.79
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5
Revenue Forecast (FY)¥3.70B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal financial leverage and a conservative balance sheet give the company durable resilience against biotech cycle shocks. Low debt preserves strategic optionality to fund R&D, partnerships or disruptions without immediate refinancing pressure, supporting multi‑month stability.
Positive Cash GenerationConsistent positive operating and free cash flow provides a sustainable internal funding source for operations and product development. Even with volatility, ongoing cash generation reduces dependency on external capital and supports execution of medium‑term strategic plans.
Revenue Rebound In 2025The 2025 revenue rebound demonstrates the company's ability to regain top‑line traction after a downturn. Sustained or repeatable recovery in sales strengthens scalability prospects and helps rebuild operating leverage if cost structure is aligned.
Bears Say
Collapsed Profitability And ReturnsEarnings and return metrics have deteriorated materially, with net margins approaching break‑even. This reduces internal capital generation, weakens ROE, and raises the bar for restoring investor returns; long‑term recovery requires sustained margin improvement.
Volatile Cash Flow QualityWhile cash generation is positive overall, sharp FCF swings and a year where OCF lagged earnings undermine predictability. Persistent cash volatility can force external financing, constrain R&D or delay commercialization investments over the medium term.
Limited Operational ScaleA small employee base suggests limited commercial scale and fewer internal resources for broad product rollouts. In biotechnology, constrained scale can slow market expansion, reduce economies of scale, and magnify the impact of execution setbacks on margins and growth.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥294.00 and its highest was ¥723.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥6.79B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Sep 10, 2026 which is in 50 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥1.89 earnings per share for the quarter, beating the consensus estimate of N/A by ¥1.89.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.5%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,847,778 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥1.89 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.631%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―